OBJECTIVE: There is a high prevalence of low bone mineral density (BMD) among patients with inflammatory bowel disease (IBD) although there is a lack of clinical data on the impact of IBD specific medications and recommended vitamin D (VD) and calcium (Ca) supplements on it. DESIGN: The cohort consisted of 150 IBD patients. The average change in BMD at the lumbar spine per year (∆BMDL/year) was calculated and the impact of clinical characteristics, medications and VD and Ca supplements was analysed. RESULTS: The prevalence of osteopenia was 69/150 (46%) and osteoporosis was identified in 15/150 (10%) patients at baseline. The presence of osteoporosis was associated with the disease duration OR=1.07 per year of disease duration (95% CI=1.01-1.14), p=0.03. The average ∆BMDL/year was 0.010 g/cm(2)/year. Among patients with no IS the ∆BMDL/year was -0.001±0.010 g/cm(2)/year, with AZA -0.001±0.013 g/cm(2)/year, with anti-TNFα 0.003±0.006 g/cm(2)/year and with COMBO 0.027±0.004 g/cm(2)/year; p<0.05 COMBO vs any other subgroup. ∆BMDL/year among patients treated with CS was -0.031±0.012 g/cm(2)/year versus CS free patients 0.013±0.004 g/cm(2)/year; p<0.001. There was no effect of VD/Ca supplementation on BMDL. CONCLUSIONS: The prevalence of low BMD was 55%. Duration of disease was the only independent predictor of low BMD. The BMDL was reduced by high cumulative dose of CS and improved by combined anti-TNFα/AZA therapy. The supplementation with recommended doses of VD and Ca had no effect on BMDL.
OBJECTIVE: There is a high prevalence of low bone mineral density (BMD) among patients with inflammatory bowel disease (IBD) although there is a lack of clinical data on the impact of IBD specific medications and recommended vitamin D (VD) and calcium (Ca) supplements on it. DESIGN: The cohort consisted of 150 IBDpatients. The average change in BMD at the lumbar spine per year (∆BMDL/year) was calculated and the impact of clinical characteristics, medications and VD and Ca supplements was analysed. RESULTS: The prevalence of osteopenia was 69/150 (46%) and osteoporosis was identified in 15/150 (10%) patients at baseline. The presence of osteoporosis was associated with the disease duration OR=1.07 per year of disease duration (95% CI=1.01-1.14), p=0.03. The average ∆BMDL/year was 0.010 g/cm(2)/year. Among patients with no IS the ∆BMDL/year was -0.001±0.010 g/cm(2)/year, with AZA -0.001±0.013 g/cm(2)/year, with anti-TNFα 0.003±0.006 g/cm(2)/year and with COMBO 0.027±0.004 g/cm(2)/year; p<0.05 COMBO vs any other subgroup. ∆BMDL/year among patients treated with CS was -0.031±0.012 g/cm(2)/year versus CS free patients 0.013±0.004 g/cm(2)/year; p<0.001. There was no effect of VD/Ca supplementation on BMDL. CONCLUSIONS: The prevalence of low BMD was 55%. Duration of disease was the only independent predictor of low BMD. The BMDL was reduced by high cumulative dose of CS and improved by combined anti-TNFα/AZA therapy. The supplementation with recommended doses of VD and Ca had no effect on BMDL.
Authors: Helioswilton Sales-Campos; Patrícia R de Souza; Paulo J Basso; Viviani Nardini; Angelica Silva; Fernanda Banquieri; Vanessa B F Alves; Javier E L Chica; Auro Nomizo; Cristina R B Cardoso Journal: Immunology Date: 2016-10-07 Impact factor: 7.397
Authors: José Miranda-Bautista; Cristina Verdejo; Alicia Díaz-Redondo; Irene Bretón; José M Bellón; María Dolores Pérez-Valderas; Aránzazu Caballero-Marcos; Marta de Dios-Lascuevas; Elena González-Río; Cristina García-Sánchez; Ignacio Marín-Jiménez; Rafael Bañares; Luis Menchén Journal: Therap Adv Gastroenterol Date: 2019-07-31 Impact factor: 4.409
Authors: Robert Venning Bryant; Christopher G Schultz; Soong Ooi; Charlotte Goess; Samuel Paul Costello; Andrew D Vincent; Scott N Schoeman; Amanda Lim; Francis Dylan Bartholomeusz; Simon P L Travis; Jane Mary Andrews Journal: Nutrients Date: 2018-09-01 Impact factor: 5.717
Authors: J Jasper Deuring; Meng Li; Wanlu Cao; Sunrui Chen; Wenshi Wang; Colin de Haar; C Janneke van der Woude; Maikel Peppelenbosch Journal: PLoS One Date: 2019-10-03 Impact factor: 3.240